Sarah Romano Net Worth & Insider Trades
Sarah Romano - Chief Financial Officer, Eyegate Pharmaceuticals Inc
What is Sarah Romano's Net Worth?
The current estimated net worth of Eyegate Pharmaceuticals Inc's Chief Financial Officer, Sarah Romano, is estimated to be about $761.07K . Sarah Romano owns about 262,113 units of Eyegate Pharmaceuticals Inc common stock. In the last 4 years at Eyegate Pharmaceuticals Inc, Sarah Romano has sold an estimated value of $26.67K worth.
What is Sarah Romano's Past Insider Trading?
Sarah Romano's largest purchase order was 10,000 units , worth over $10K on August 17, 2017. Sarah Romano's largest sale order was 19,750 units , worth over $4.67K on July 15, 2019. In total, Sarah Romano has made about 38 transactions over 4 years of their time at Eyegate Pharmaceuticals Inc. Sarah Romano usually trades in February, with the busiest year in 2020.
Attention insiders: Dive deeper into market movements and stay ahead of the curve with Benzinga Pro! From up-to-the-second news to audio squawks and interactive data tools, it's everything you need to supercharge your trading strategy. Experience the Benzinga Pro advantage today and transform the way you trade with our exclusive free trial!
Sarah Romano
Date Range: All Time
Ticker
|
Type
|
Value
|
Price per Share
|
Shares
|
Filing Date
| ||
|---|---|---|---|---|---|---|---|
| No matching records found | |||||||
InsideArbitrage
What was Sarah Romano's Salary in 2020 ?
As Chief Financial Officer of Eyegate Pharmaceuticals Inc, Sarah Romano has a total base salary of $264,361 . Sarah Romano received compensation valued at about $453,643 in 2020 after becoming Chief Financial Officer. The vast majority of their compensation came in the form of a bonus of $60,000 , stock awards of $64,641 , option awards of $64,641 , and
What is Sarah Romano's' Mailing Address?
- Mailing address is 271 Waverly Oaks Road Waltham MA 02452 MA
Eyegate Pharmaceuticals Inc Executive Compensation
Name |
Year
|
Salary
|
Bonus
|
Stock Awards
|
Option Awards
|
Other Compensation
|
Total
|
|---|---|---|---|---|---|---|---|
| Stephen From | 2020 | $400,000 | $160,000 | $129,282 | $193,923 | - | $883,205 |
| Stephen From | 2019 | $400,000 | $106,600 | - | $94,740 | - | $601,340 |
| Sarah Romano | 2020 | $264,361 | $60,000 | $64,641 | $64,641 | - | $453,643 |
| Sarah Romano | 2019 | $250,000 | $86,010 | - | $23,685 | - | $359,695 |
| Michael Manzo | 2020 | $250,000 | $60,000 | $48,481 | $48,481 | - | $406,962 |
| Michael Manzo | 2019 | $250,000 | $94,167 | - | $23,685 | - | $367,852 |
| No matching records found | |||||||
Source: https://www.sec.gov/Archives/edgar/data/1372514/000110465921058990/tm2114484-1_def14a.htm
What are Eyegate Pharmaceuticals Inc's Past Insider Trades?
Eyegate Pharmaceuticals Inc's most recent insider trade came on August 3, 2021 by Armistice Capital Llc, Armistice Capital Master Fund Ltd and Steven Boyd who sold 260,963 units worth $646.61K . In the last 6 years, insiders at Eyegate Pharmaceuticals Inc have sold an estimated value of $15.73M and bought an estimated value of $20.29M worth of shares. Insider trading is most common in February, with the busiest year in 2020. The most active traders at the company are Stephen From, Executive Chairman, Michael Manzo, VP Engineering, and Brenda Mann, VP Research & Development .
EYEGATE PHARMACEUTICALS INC Insider Trades
Date Range: All Time
Insider Names
|
Type
|
Value
|
Price per Share
|
Shares
|
Filing Date
| ||
|---|---|---|---|---|---|---|---|
| No matching records found | |||||||